Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

  • The trial showed that C21 reduced the need for supplemental oxygen and mechanical ventilation, indicating faster patient recovery. C21 was also found to be safe and well tolerated.
  • Data encouraged Vicore to move into phase 3 with readout on-track for H1 2022.

Gothenburg, October 25, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a peer reviewed clinical journal, published by The Lancet. The paper is available online via this link.

"The positive results from the phase 2 trial are very encouraging and led Vicore to further investigate C21 in the currently ongoing phase 3 trial" said Göran Tornling, senior adviser to Vicore and co-author of the ATTRACT publication "We are very pleased to be able to share this important data through publication in EClinicalMedicine".

The phase 2 trial ATTRACT1 was organized and conducted in the full heat of the 2020 COVID-19 outbreak.  Although the primary endpoint (reduction in CRP) was not different between C21 and placebo treated patients after seven days of treatment, secondary analyses of clinical outcomes strongly suggest that C21 treatment is beneficial in reducing the extended need for supplemental oxygen therapy. In this 106 patient phase 2 trial, data suggest that treatment with C21 may have reduced progression to more severe respiratory disease.

"We see a continued need of efficient treatments for hospitalized patients with COVID-19. The vaccination rate is still low with only 37%* vaccinated with two doses world-wide and new mutations of the virus remain a challenge. Provided that we can confirm the positive results in the phase 3 trial, C21 has the potential to become one of these treatments in addition to antivirals" said Carl-Johan Dalsgaard, CEO of Vicore and corresponding author on the paper.

The Chief Investigator of ATTRACT was Professor Joanna Porter, consultant in respiratory and general medicine at University College London Hospitals NHS Foundation Trust (UCLH) and a professor in respiratory medicine at UCL.

ATTRACT-3, ongoing phase 3-trial in COVID-19
The pivotal phase 3 trial ATTRACT-3was approved by the FDA in June 2021 based on results from the ATTRACT trial. ATTRACT-3 is a randomized, double-blind, placebo-controlled, global, phase 3 trial which will include 600 adult patients hospitalized with COVID-19 and requiring oxygen support but not mechanical ventilation. The primary objective is to evaluate the effect of C21 on recovery from COVID-19. ATTRACT-3 is recruiting and expected to deliver top-line data in H1 2022.

C21 - a first-in-class AT2R agonist            
C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the "protective arm" of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage. The compound is currently in a phase 2 proof-of-concept trial in IPF and in a pivotal phase 3 trial in COVID-19.

LifeArc funding                         
The ATTRACT study received £1.5 million in funding from the UK charity charity LifeArc - Coronavirus (COVID-19) Therapeutics, a £10 million fund launched on 20 March 2020 to support research and testing of therapeutics that could be rapidly deployed to help address COVID-19.

For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
E-mail: [email protected]

This information was submitted for publication on October 25, 2021, at 08:00 CET.

*Our world in data

1. NCT04452435

2. NCT04880642

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a rare disease pharmaceutical company focused on severe lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is based on a new formulation and delivery route of thalodimide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2R agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com

Delårsrapport juli - september 2021

Göteborg, 4 november 2021 - Vicore Pharma Holding AB (publ) publicerar sin delårsrapport för tredje kvartalet 2021.


Interim report July - September 2021

Gothenburg, November 4, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2021.


Vicores C21 minskar långsiktiga lungskador efter COVID-19 i ATTRACT fas 2 uppföljningsstudien

  • Resultaten visade närmare 50% minskning av uppkomna lungskador efter behandling med C21  jämfört med placebo
  • Dessa positiva fynd tillsammans med tidigare kliniska resultat1 talar för att C21 kan påskynda återhämtningen  
  • C21 utvärderas för närvarande vid en fas 3-studie i COVID-19 patienter

Göteborg,  2 november, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsföretag som utvecklar innovativa behandlingar mot svåra lungsjukdomar, meddelar idag resultat att behandling med bolagets AT2R agonist, C21, minskar långsiktiga lungskador hos sjukhusinlagda COVID-19 patienter.


Lancets EClinicalMedicine publicerar resultat från fas 2-studie med C21 i COVID-19

  • Studien visade att C21 minskade behovet av syrgas- och respiratorbehandling, vilket indikerar en snabbare återhämtning. C21 var också säkert och väl tolererat.
  • Resultaten låg till grund för Vicores beslut att gå vidare med en fas 3-studie vilken beräknas vara klar första halvåret 2022.

Göteborg, 25 oktober, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsföretag som utvecklar innovativa behandlingar mot svåra lungsjukdomar, meddelar idag att resultaten från fas 2-studien ATTRACT med angiotensin II typ 2 receptor agonisten C21 i COVID-19 har publicerats i EClinicalMedicine, en expertgranskad vetenskaplig tidskrift utgiven av The Lancet. Publikationen finns tillgänglig online via denna länk.


Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

  • The trial showed that C21 reduced the need for supplemental oxygen and mechanical ventilation, indicating faster patient recovery. C21 was also found to be safe and well tolerated.
  • Data encouraged Vicore to move into phase 3 with readout on-track for H1 2022.

Gothenburg, October 25, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a peer reviewed clinical journal, published by The Lancet. The paper is available online via this link.


Vicore offentliggör valberedningen inför årsstämman 2022

Göteborg, 20 oktober, 2021 - Vicore Pharma Holding AB (publ) har utsett valberedningen inför årsstämman 2022. De tre största aktieägarna per den 31 augusti 2021 har erbjudits att utse en ledamot till valberedningen vardera, i enlighet med beslutet som togs på årsstämman den 11 maj 2021.


Vicore håller webbinarium om C21 för behandling av idiopatisk lungfibros (IPF)

Webbinariet hålls torsdagen den 30 september @16:00 CET (10:00 am EST) med läkarna och IPF-experterna, Prof. Toby Maher och Prof. Joanna Porter.

Göteborg, 22 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel mot svåra lungsjukdomar meddelar idag att bolaget kommer att hålla ett webbinarium om C21, Vicores ledande läkemedelsmolekyl, för behandling av idiopatisk lungfibros (IPF), torsdagen den 30 september kl. 16:00 CET (10:00 am EST).


Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)

Webinar on Thursday, September 30 @ 16:00 CET (10AM ET) with the medical doctors and IPF experts Prof. Toby Maher and Prof. Joanna Porter.

Gothenburg, September 22, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced it will host a key opinion leader (KOL) webinar on C21, the company's lead asset for the treatment of idiopathic pulmonary fibrosis (IPF) on Thursday, September 30, 2021 at 16:00 CET (10 AM Eastern Time).


Vicore erhåller SARS coronavirus-patent för C21 i USA

Göteborg, 22 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsföretag som utvecklar innovativa behandlingar mot svåra lungsjukdomar, meddelar idag att US Patent and Trademark Office (USPTO) har beviljat patentet US11,123,329 som omfattar användningen av C21 för att behandla infektioner orsakade av Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), inklusive SARS-CoV-2.


Vicore behandlar första COVID-19 patienterna i den globala fas 3-studien ATTRACT-3

Göteborg, 17 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel mot svåra lungsjukdomar meddelar idag att de första patienterna i bolagets globala fas 3-studie med C21 i COVID-19 (ATTRACT-3) doserats.

  • Tidigare rapporterade positiva resultat från fas 2-studien ger starkt stöd för fortsatt utvärdering av Vicores AT2 receptor agonist C21 i COVID-19
  • Den pivotala fas 3-studien är nu godkänd i USA, Ukraina, Sydafrika, Brasilien, Tjeckien, Filippinerna och Indien med syftet att undersöka effektiviteten och säkerheten av C21 på sjukhusinlagda patienter med COVID-19

Göteborg, 17 september, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel mot svåra lungsjukdomar meddelar idag att de första patienterna i bolagets globala fas 3-studie med C21 i COVID-19 (ATTRACT-3) doserats.


Vicore starts dosing of first COVID-19 patients in the global phase 3 trial ATTRACT-3

Gothenburg, September 17, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today announces the dosing of the first patients in the company's global phase 3 trial of C21 in COVID-19 (ATTRACT-3).

  • Previously reported positive phase 2 trial results strongly support further evaluation of the Vicore AT2 receptor agonist C21 in COVID-19
  • The pivotal phase 3 trial is currently approved in the US, Ukraine, South Africa, Brazil, Czechia, Philippines and India to investigate the efficacy and safety of C21 in hospitalized patients with COVID-19

Vicore stärker sin ledningsgrupp

Göteborg, 27 augusti, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), ett särläkemedelsbolag som utvecklar innovativa läkemedel för fibrotiska lungsjukdomar som idiopatisk lungfibros (IPF), meddelar idag att bolagets ledningsgrupp stärks med tre seniora rekryteringar när bolagets forsknings- och utvecklingsaktiviteter närmar sig viktiga kommersiella milstolpar.


Delårsrapport april - juni 2021

Göteborg, 26 augusti 2021 - Vicore Pharma Holding AB (publ) publicerar sin delårsrapport för andra kvartalet 2021.


Interim report April - June 2021

Gothenburg, August 26, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2021.


Vicore meddelar om deltagande i investerarmöten under juni 2021

Göteborg, 15 juni, 2021 - Vicore Pharma Holding AB (publ) ("Vicore"), som ett särläkemedelsbolag som utvecklar innovativa läkemedel mot fibrotiska lungsjukdomar som idiopatisk lungfibros (IPF), meddelar idag om deltagande i två investerarkonferenser under juni månad 2021.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted